Medtronic has unveiled three-year real-world evidence demonstrating sustained improvements in glycemic control with its MiniMed 780G automated insulin delivery (AID) system.
MiniMed 780G, the company’s latest-generation AID platform, features meal detection technology and delivers automatic insulin adjustments and corrections every five minutes for both basal (background) and bolus (mealtime) needs.
Presented at the European Association for the Study of Diabetes (EASD) 61st Annual Meeting in Vienna, the data revealed rapid and sustained improvements in glycemic outcomes for people with Type 1 diabetes, while significantly reducing the burden of daily insulin management. The results follow recent U.S. Food and Drug Administration (FDA) clearances for the system, coming ahead of Medtronic’s planned spin-off of its Diabetes unit into a standalone public company.
The analysis included 1,145 participants aged 16 and older from across Europe, the Middle East, and Africa (EMEA). Users experienced a swift increase in time spent in the target glucose range (70–180 mg/dL), reaching 78.6% and maintaining this level over 36 months.
Automation also increased significantly over time. The percentage of insulin delivered via autocorrections rose from 0% to 12.9% initially and climbed to 17.2% by year three, while user-initiated insulin doses dropped from 52.4% to 41.5%. Use of optimal system settings—such as a 100 mg/dL glucose target and two-hour active insulin time—also rose, reflecting growing confidence among users and clinicians.
“These findings highlight the significant ability of the MiniMed 780G system to improve diabetes care, providing lasting clinical and lifestyle advantages,” said Jennifer McVean, Senior Medical Affairs Director at Medtronic Diabetes. “As we move closer to fully automated insulin delivery, empowering people with type 1 diabetes to trust and rely on these technologies will be key to achieving better outcomes and improved quality of life.”